Form 4 for CLDX Celldex Therapeutics, Inc.
Accepted 2024-06-03 00:00:00 ET · period of report 2024-05-30 · accession 0001415889-24-015148 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-06-03 | 2024-05-30 | CLDX | Heath-Chiozzi Margo | SVP OF REGULATORY AFFAIRS | M - OptEx | $3.75 | +33.7K | 41.2K | +453% | +$126.3K |
| D | 2024-06-03 | 2024-05-30 | CLDX | Heath-Chiozzi Margo | SVP OF REGULATORY AFFAIRS | S - Sale+OE | $34.07 | -38.7K | 7,094 | -85% | -$1.32M |
| DM | 2024-06-03 | 2024-05-30 | CLDX | Heath-Chiozzi Margo | SVP OF REGULATORY AFFAIRS | M - OptEx | $0.00 | -33.7K | 81.4K | -29% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-05-30 | M | A | 2,608 | $10.38 | 45,813 | D | — | — | |
| 2 | Common | Common Stock | 2024-05-30 | M | A | 2,043 | $9.02 | 43,205 | D | — | — | |
| 3 | Common | Common Stock | 2024-05-30 | M | A | 29,068 | $2.78 | 41,162 | D | — | — | (F1) Includes 847 shares of common stock acquired under the Celldex Therapeutics, Inc. 2004 Employee Stock Purchase Plan. |
| 4 | Common | Common Stock | 2024-05-30 | S | D | 38,719 | $34.07 | 7,094 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.850 to $34.445 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. |
| 5 | Derivative | Incentive Stock Option (Right to Buy) | 2024-05-30 | M | D | 29,068 | $0.00 | 12,732 | D | $2.78 · — to 2029-06-19 | 29,068 Common Stock | (F3) As of June 19, 2023, the option is fully vested. |
| 6 | Derivative | Incentive Stock Option (Right to Buy) | 2024-05-30 | M | D | 2,043 | $0.00 | 6,289 | D | $9.02 · — to 2028-06-13 | 2,043 Common Stock | (F4) As of June 13, 2022, the option is fully vested. |
| 7 | Derivative | Incentive Stock Option (Right to Buy) | 2024-05-30 | M | D | 2,608 | $0.00 | 81,392 | D | $10.38 · — to 2030-06-18 | 2,608 Common Stock | (F5) 25% vested on June 18, 2021 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. |